The U.S. Food and Drug Administration yesterday asked Endo Pharmaceuticals to remove its opioid pain medication Opana ER from the market, citing the potential for the reformulated drug to be abused. “We will continue to take regulatory steps when we see situations where an opioid product’s risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Perspective
In Michigan, African Americans make up 14% of the population … but account for 40% of the COVID-19 deaths. In Chicago: 30% of the population … and 46% of the…
Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
The Department of Health and Human Services’ Office of Minority Health May 1 announced it will provide funding to help deliver important COVID-19-related…
Headline
Hospitals and health systems continue to provide care for our most vulnerable communities by addressing social needs, educating on COVID-19 risks and…
Headline
A study of 305 hospitalized adult COVID-19 patients in Georgia found an overrepresentation of black patients, with over a quarter lacking known risk factors,…
Blog
The AHA is committed to ensuring that all people, regardless of background or zip code, have equitable access to quality health care. As the COVID-19 pandemic…